Fjarde AP Fonden Fourth Swedish National Pension Fund Raises Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 72.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,412 shares of the company’s stock after buying an additional 17,440 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in IDEXX Laboratories were worth $23,269,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in IDXX. SHP Wealth Management bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $26,000. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the third quarter worth approximately $26,000. Park Place Capital Corp bought a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth $30,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories in the third quarter worth $36,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $557.80 on Friday. The stock has a market cap of $44.00 billion, a P/E ratio of 41.08, a PEG ratio of 3.05 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company’s fifty day simple moving average is $555.31 and its two-hundred day simple moving average is $609.16.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the business posted $2.91 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IDXX. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. UBS Group cut their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. Finally, Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.